Search Medical Condition
Please enter condition
Please choose location

Jefferson City, Missouri Clinical Trials

A listing of Jefferson City, Missouri clinical trials actively recruiting patient volunteers.

RESULTS

Found (75) clinical trials

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).

Phase N/A

0.0 miles

Learn More »

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Oversight Authorities continued: Colombia- pending regulatory approval

Phase

2.39 miles

Learn More »

International Hernia Mesh Registry

To help identify best practices leading to lower recurrence rates and decreases in chronic pain associated with the hernia repair procedure.

Phase N/A

2.39 miles

Learn More »

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other agents in a Genentech/Roche-sponsored parent study who are active and deriving benefit at the closure of parent study are eligible for continued treatment in this study.

Phase

2.39 miles

Learn More »

Ixazomib Citrate Lenalidomide Dexamethasone and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

This phase III randomized clinical trial was designed to assess the impact of the addition of ixazomib, lenalidomide, and dexamethasone to zoledronic acid the multiple myeloma progression rate at 5 years. A dynamic allocation procedure will be used to allocate an equal number of patients to each of the treatment ...

Phase

3.82 miles

Learn More »

Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas

PRIMARY OBJECTIVES: I. To determine the activity of a smoothened, frizzled class receptor (SMO) and PTCH1 inhibitor in patients with meningiomas harboring SMO mutations as measured by 6-month progression free survival (PFS) and response rate. II. To determine the activity of a FAK inhibitor in patients with meningiomas harboring neurofibromin ...

Phase

3.82 miles

Learn More »

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.

Phase

3.82 miles

Learn More »

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.

Phase

3.82 miles

Learn More »

informCLL : A Disease Registry for Patients With Chronic Lymphocytic Leukemia

InformCLL is a multicenter, prospective, observational registry of CLL patients designed to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL therapies/regimens. The registry will provide information on regimens used to treat first-line and later lines of CLL/SLL as ...

Phase N/A

3.82 miles

Learn More »

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Patients will be randomised in 1:1 ratio to either olaparib or placebo. Randomisation will be stratified by Hormone receptor status (ER and/or PgR positive/HER2 negative versus TNBC), prior neoadjuvant versus adjuvant chemotherapy and prior platinum use for breast cancer. Randomised patients will receive study treatment for up to a maximum ...

Phase

3.82 miles

Learn More »